These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 33566044)

  • 21. Geniposide alleviates non-alcohol fatty liver disease via regulating Nrf2/AMPK/mTOR signalling pathways.
    Shen B; Feng H; Cheng J; Li Z; Jin M; Zhao L; Wang Q; Qin H; Liu G
    J Cell Mol Med; 2020 May; 24(9):5097-5108. PubMed ID: 32293113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fenofibrate alleviates NAFLD by enhancing the PPARα/PGC-1α signaling pathway coupling mitochondrial function.
    Wang X; Wang J; Ying C; Xing Y; Su X; Men K
    BMC Pharmacol Toxicol; 2024 Jan; 25(1):7. PubMed ID: 38173037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet.
    Liou CJ; Lee YK; Ting NC; Chen YL; Shen SC; Wu SJ; Huang WC
    Cells; 2019 May; 8(5):. PubMed ID: 31083505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study on the attenuated effect of Ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease.
    Yang Y; Chen J; Gao Q; Shan X; Wang J; Lv Z
    Toxicology; 2020 Dec; 445():152599. PubMed ID: 32976958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress.
    Qiang X; Xu L; Zhang M; Zhang P; Wang Y; Wang Y; Zhao Z; Chen H; Liu X; Zhang Y
    Biochem Biophys Res Commun; 2016 Apr; 472(4):603-9. PubMed ID: 26970305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease
    Li CX; Gao JG; Wan XY; Chen Y; Xu CF; Feng ZM; Zeng H; Lin YM; Ma H; Xu P; Yu CH; Li YM
    World J Gastroenterol; 2019 Sep; 25(34):5120-5133. PubMed ID: 31558861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scutellarin ameliorates nonalcoholic fatty liver disease through the PPARγ/PGC-1α-Nrf2 pathway.
    Zhang X; Ji R; Sun H; Peng J; Ma X; Wang C; Fu Y; Bao L; Jin Y
    Free Radic Res; 2018 Feb; 52(2):198-211. PubMed ID: 29400110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Astaxanthin Alleviates Nonalcoholic Fatty Liver Disease by Regulating the Intestinal Flora and Targeting the AMPK/Nrf2 Signal Axis.
    Li Y; Liu J; Ye B; Cui Y; Geng R; Liu S; Zhang Y; Guo W; Fu S
    J Agric Food Chem; 2022 Aug; 70(34):10620-10634. PubMed ID: 35973099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Total flavonoids of Broussonetia papyrifera alleviate non-alcohol fatty liver disease via regulating Nrf2/AMPK/mTOR signaling pathways.
    Wang Q; Wei Y; Wang Y; Yu Z; Qin H; Zhao L; Cheng J; Shen B; Jin M; Feng H
    Biochim Biophys Acta Mol Cell Biol Lipids; 2024 Jun; 1869(5):159497. PubMed ID: 38649009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Berbamine induced AMPK activation regulates mTOR/SREBP-1c axis and Nrf2/ARE pathway to allay lipid accumulation and oxidative stress in steatotic HepG2 cells.
    Sharma A; Anand SK; Singh N; Dwivedi UN; Kakkar P
    Eur J Pharmacol; 2020 Sep; 882():173244. PubMed ID: 32526241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor γ coactivator 1α.
    Wang Y; Zhao X; Lotz M; Terkeltaub R; Liu-Bryan R
    Arthritis Rheumatol; 2015 May; 67(8):2141-53. PubMed ID: 25940958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
    Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
    Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling.
    Kim MH; Seong JB; Huh JW; Bae YC; Lee HS; Lee DS
    Redox Biol; 2020 Jan; 28():101315. PubMed ID: 31505325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. α-Lactalbumin Peptide Asp-Gln-Trp Ameliorates Hepatic Steatosis and Oxidative Stress in Free Fatty Acids-Treated HepG2 Cells and High-Fat Diet-Induced NAFLD Mice by Activating the PPARα Pathway.
    Chen H; Ma Y; Qi X; Tian J; Ma Y; Niu T
    Mol Nutr Food Res; 2023 Aug; 67(16):e2200499. PubMed ID: 37354055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Celastrol ameliorates liver metabolic damage caused by a high-fat diet through Sirt1.
    Zhang Y; Geng C; Liu X; Li M; Gao M; Liu X; Fang F; Chang Y
    Mol Metab; 2017 Jan; 6(1):138-147. PubMed ID: 28123944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
    Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
    Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic SIRT1/PGC-1α pathway.
    Meng D; Yin G; Chen S; Zhang X; Yu W; Wang L; Liu H; Jiang W; Sun Y; Zhang F
    Eur J Pharmacol; 2024 Aug; 977():176737. PubMed ID: 38866362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gentiopicroside Ameliorates Oxidative Stress and Lipid Accumulation through Nuclear Factor Erythroid 2-Related Factor 2 Activation.
    Jin M; Feng H; Wang Y; Yan S; Shen B; Li Z; Qin H; Wang Q; Li J; Liu G
    Oxid Med Cell Longev; 2020; 2020():2940746. PubMed ID: 32655764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
    Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
    Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AMPK activation by liquiritigenin inhibited oxidative hepatic injury and mitochondrial dysfunction induced by nutrition deprivation as mediated with induction of farnesoid X receptor.
    Jung EH; Lee JH; Kim SC; Kim YW
    Eur J Nutr; 2017 Mar; 56(2):635-647. PubMed ID: 26646674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.